Skip to content

OTC Mouthpiece for Snoring

In-Home Study of Intraoral Device for Reducing Snoring Among Habitual Snorers

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03128307
Enrollment
604
Registered
2017-04-25
Start date
2017-04-07
Completion date
2017-08-10
Last updated
2017-12-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Snoring

Brief summary

Online patient registration to participate in clinical trial to test OTC mouthpiece that controls position of the tongue to reduce snoring.

Detailed description

Patient will complete informed consent, inclusion/exclusion criteria, sleep apnea and snoring surveys online. If patient meets all criteria for the study, patient will be provided with a treatment device for use for a 10 day treatment period. Patient will complete the trial upon providing final online surveys.

Interventions

DEVICEZyppah Anti-snoring Appliance

Use of an OTC mouth guard at night to prevent snoring

Sponsors

Zyppah, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
DOUBLE (Caregiver, Investigator)

Masking description

The data is compiled and analyzed by an outside, independent organization

Intervention model description

Patient serves as their own control

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Over 18 years of age * Living in the United States * Signing the Informed Consent Form

Exclusion criteria

* Missing teeth (as the device won't be properly fitted) * Any severe breathing or respiratory disorder, such as chronic asthma, emphysema, COPD, or a similar condition * Poor dental health, such as severe gum disease, loose teeth, an abscess, mouth sores, or bleeding gums * A dental implant placed within the last three months * Diagnosed with a Temporomandibular joint condition (TMJ) * Actively experiencing any mouth or jaw pain, including clenching of the teeth, grinding, or any other physical injury to the jaw or teeth * Full dentures * Braces * Diagnosis of sleep apnea * Less than 18 years of age

Design outcomes

Primary

MeasureTime frameDescription
Snoring Severity ScaleBaseline and 10 DaysThe Snoring Severity Scale (SSS) is a 9-point, validated scale to measure the severity of snoring. A total of three questions are asked: 1) How often do you snore, 2) How long do you snore, and 3) How audible is your snoring. Answers for each of these questions are summed for a total SSS score. A score of '0' would indicate no snoring at all, while a score of '9' would indicate the most severe snoring as measured by the SSS. Outcome measure reported as change with use of the device over pre-trial. In this case, a negative ('-') would represent improvement in snoring symptoms, while a positive ('+') number would indicate an increase in snoring severity.
Visual-Analogue Scale, Self-Reported Snoring HabitsBaseline and 10 DaysQuantitative assessment on 1-10 scale. Outcome measurement reported as a percentage change from pre-trial with use of the device. A negative ('-') percentage would indicate a reduction in snoring symptoms as measured by the VAS, while a positive percentage ('+') result would indicate an increase in the measured symptom.

Countries

United States

Participant flow

Recruitment details

Subjects recruited online. A total of 764 expressed interest in the trial. 143 potential subjects either opted not to participate or did not meet the inclusion/exclusion criteria.

Participants by arm

ArmCount
Clinical Trial Participants
Subjects who received the Zyppah Anti-Snoring device and were entered into the clinical study. Subjects were asked to use the device for ten consecutive nights and then fill out an online form assessing their experience with the device.
570
Total570

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyLost to Follow-up29
Overall StudyWithdrawal by Subject5

Baseline characteristics

CharacteristicClinical Trial Participants
Age, Continuous48 years
STANDARD_DEVIATION 11
How Frequently Do you Snore: VAS (1-10)8.94 units on a scale
STANDARD_DEVIATION 2.83
How Much Does your Snoring bother YOUR PARTNER: VAS (1-10)8.92 units on a scale
STANDARD_DEVIATION 1.98
How Much Does your Snoring bother YOU: VAS (1-10)5.08 units on a scale
STANDARD_DEVIATION 2.91
Race and Ethnicity Not Collected— Participants
Sex: Female, Male
Female
105 Participants
Sex: Female, Male
Male
465 Participants
Snoring Severity Scale (1-9)6.2 units on a scale
STANDARD_DEVIATION 1.57

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 570
other
Total, other adverse events
1 / 570
serious
Total, serious adverse events
0 / 570

Outcome results

Primary

Snoring Severity Scale

The Snoring Severity Scale (SSS) is a 9-point, validated scale to measure the severity of snoring. A total of three questions are asked: 1) How often do you snore, 2) How long do you snore, and 3) How audible is your snoring. Answers for each of these questions are summed for a total SSS score. A score of '0' would indicate no snoring at all, while a score of '9' would indicate the most severe snoring as measured by the SSS. Outcome measure reported as change with use of the device over pre-trial. In this case, a negative ('-') would represent improvement in snoring symptoms, while a positive ('+') number would indicate an increase in snoring severity.

Time frame: Baseline and 10 Days

ArmMeasureValue (MEAN)Dispersion
Clinical Trial ParticipantsSnoring Severity Scale-4.1 units on a scaleStandard Deviation 0.082
p-value: <0.0001t-test, 2 sided
Primary

Visual-Analogue Scale, Self-Reported Snoring Habits

Quantitative assessment on 1-10 scale. Outcome measurement reported as a percentage change from pre-trial with use of the device. A negative ('-') percentage would indicate a reduction in snoring symptoms as measured by the VAS, while a positive percentage ('+') result would indicate an increase in the measured symptom.

Time frame: Baseline and 10 Days

ArmMeasureGroupValue (NUMBER)
Clinical Trial ParticipantsVisual-Analogue Scale, Self-Reported Snoring HabitsHow much does your snoring bother YOU?-51.5 percent change
Clinical Trial ParticipantsVisual-Analogue Scale, Self-Reported Snoring HabitsHow much does your snoring bother YOUR PARTNER?-60.2 percent change
Clinical Trial ParticipantsVisual-Analogue Scale, Self-Reported Snoring HabitsHow frequently do you snore?-56.8 percent change
p-value: <0.0001t-test, 2 sided

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026